Evaxion, a pioneering force in the biotech industry, is set to create waves at the upcoming ESMO Immuno-Oncology Congress by unveiling a revolutionary AI-driven cancer vaccine concept. This innovative approach aims to transform cancer treatment through individualized vaccines that harness the power of artificial intelligence.
At the heart of Evaxion’s groundbreaking system is its use of AI to meticulously analyze patient data, with a particular focus on ERV tumor antigens—key markers that are often shared among multiple cancer patients. By identifying these shared antigens, the AI can tailor vaccines to target specific types of cancer, and in some scenarios, even personalize them for individual patients.
The company, known for its discretion regarding its proprietary AI systems, has developed four specialized models, each playing a crucial role. The EDEN model hunts for antigens that elicit robust immune responses against bacterial infections. OBSERV concentrates on complementing existing patient antigens, especially ERVs, which are remnants of ancient immune responses encoded in human DNA. Meanwhile, PIONEER scans for patient-specific antigens that could be leveraged through immunotherapy. Lastly, RAVEN assesses the effectiveness of potential vaccine candidates. Together, these models are designed to pinpoint the optimal immune treatment tailored to each cancer patient.
Evaxion has dubbed this comprehensive approach AI-Immunology and has been committed to developing it since the company’s inception. Since its IPO and subsequent investor engagement in 2021, Evaxion has secured significant partnerships, including a promising deal with Merck & Co. This milestone-dependent agreement could potentially bring in over a billion dollars, assuming all objectives are met. Currently, Evaxion’s commercial portfolio features vaccines for ailments such as Staph infections and gonorrhea.
The company is poised to present compelling preclinical data at the congress. This evidence, derived from human cell studies and mouse tumor models, highlights the effectiveness of precision ERV vaccine targets in eliciting human T-cell responses and inhibiting tumor growth in mice. Evaxion’s AI-Immunology platform excels in identifying ERV antigens, which can pave the way for customized cancer vaccines suitable for a wide array of patients, particularly those who do not respond to traditional cancer immunotherapy.
By tapping into the potential of ERVs as vaccine targets, Evaxion is setting the stage for precision cancer vaccines that transcend diverse immune system characteristics, broadening the therapeutic horizon for countless patients. These preclinical successes bolster Evaxion’s ongoing efforts to augment its roster of personalized cancer vaccines, as they prepare to reveal these insights at the esteemed international congress.
